Cargando…
Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
Frameworks that associate cancer dynamic disease progression models with parametric survival models for clinical outcome have recently been proposed to support decision making in early clinical development. Here we developed such a disease progression clinical outcome model for castration-resistant...
Autores principales: | van Hasselt, JGC, Gupta, A, Hussein, Z, Beijnen, JH, Schellens, JHM, Huitema, ADR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544052/ https://www.ncbi.nlm.nih.gov/pubmed/26312162 http://dx.doi.org/10.1002/psp4.49 |
Ejemplares similares
-
Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin
por: van Hasselt, JGC, et al.
Publicado: (2015) -
Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2019) -
Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
por: van Hasselt, J. G. Coen, et al.
Publicado: (2014) -
Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
por: van Hasselt, J. G. Coen, et al.
Publicado: (2015) -
Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)